Clinical Trials Logo

Second-line Treatment clinical trials

View clinical trials related to Second-line Treatment.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05901584 Recruiting - Immunotherapy Clinical Trials

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer

NCT ID: NCT04193098 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

Start date: June 1, 2019
Phase: Phase 1
Study type: Interventional

This prospective, unicentric, open-labe phase I study is to evaluate the safety and effect of autologous cytotoxic T lymphocyte immunotherapy combination with PD-1 inhibitor in the second-line treatment of stage IIIB/IIIC/IV non-small cell lung cancer.